September 27, 2018 07:39 AM EDT

Scathing short attack from an obscure source accuses Nanjing Legend of manipulating CAR-T data — Genscript shares nosedive

Amber Tong

Genscript, the Chinese company behind overnight CAR-T star Nanjing Legend Biotech, has seen its stock nosedive after a damning short report questioned its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Scathing short attack from an obscure source accuses Nanjing Legend of manipulating CAR-T data — Genscript shares nosedive

Amber Tong

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

The election is Tuesday. What’s at stake for the pharma industry?

FDA cites Mark Cuban's drug compounding center in Dallas with sterility, quality concerns

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

Rare disease biopharma companies weigh in on FDA's new innovation hub

Is there room for MASH drugs in a GLP-1 world?

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Scathing short at­tack from an ob­scure source ac­cus­es Nan­jing Leg­end of ma­nip­u­lat­ing CAR-T da­ta — Gen­script shares nose­dive

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Scathing short attack from an obscure source accuses Nanjing Legend of manipulating CAR-T data — Genscript shares nosedive